Jefferies Financial Group Inc. Sells 179,493 Shares of Colgate-Palmolive Company $CL

Jefferies Financial Group Inc. cut its stake in Colgate-Palmolive Company (NYSE:CL – Free Report) by 86.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 28,796 shares of the company’s stock after selling 179,493 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Colgate-Palmolive were worth $2,457,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. State Street Corp grew its holdings in Colgate-Palmolive by 97.4% during the 2nd quarter. State Street Corp now owns 94,195,992 shares of the company’s stock valued at $8,635,889,000 after buying an additional 46,476,510 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Colgate-Palmolive by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 13,532,417 shares of the company’s stock worth $1,240,652,000 after purchasing an additional 1,010,872 shares in the last quarter. First Eagle Investment Management LLC lifted its stake in Colgate-Palmolive by 1.1% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,205,699 shares of the company’s stock worth $752,298,000 after purchasing an additional 88,917 shares in the last quarter. Bank of America Corp DE boosted its holdings in Colgate-Palmolive by 17.4% in the 1st quarter. Bank of America Corp DE now owns 6,637,597 shares of the company’s stock valued at $565,722,000 after purchasing an additional 986,063 shares during the period. Finally, Amundi boosted its holdings in Colgate-Palmolive by 19.9% in the 2nd quarter. Amundi now owns 6,218,257 shares of the company’s stock valued at $570,090,000 after purchasing an additional 1,033,918 shares during the period. Hedge funds and other institutional investors own 80.41% of the company’s stock.

More Colgate-Palmolive News

Here’s some of the latest news about CL:

  • Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.91 from $3.85, close to the $3.92 consensus, and nudged its FY2027 and FY2028 forecasts higher to $4.06 and $4.38, respectively. These revisions suggest modest confidence in longer-term earnings growth. Zacks Research Has Bullish Forecast for CL FY2026 Earnings
  • Neutral Sentiment: A comparison with Kimberly-Clark highlighted Colgate-Palmolive’s leading global oral-care position and its pet-nutrition business as potential growth diversifiers, but the article did not report a new company-specific catalyst. Colgate-Palmolive vs. Kimberly-Clark
  • Negative Sentiment: A Colgate-Palmolive executive vice president sold $401,677 worth of company shares. Insider sales can weigh on sentiment, although a single transaction does not necessarily indicate a change in the company’s outlook. Insider Selling: Colgate-Palmolive EVP Sells Stock

Insider Activity

In other news, CEO Noel R. Wallace sold 20,000 shares of Colgate-Palmolive stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $100.26, for a total value of $2,005,200.00. Following the sale, the chief executive officer directly owned 359,700 shares in the company, valued at approximately $36,063,522. This trade represents a 5.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregory Malcolm sold 4,100 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $97.97, for a total value of $401,677.00. Following the transaction, the executive vice president directly owned 10,061 shares in the company, valued at $985,676.17. This trade represents a 28.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 77,414 shares of company stock worth $7,613,786 in the last quarter. Insiders own 0.43% of the company’s stock.

Colgate-Palmolive Stock Down 0.1%

CL opened at $99.62 on Monday. Colgate-Palmolive Company has a 12 month low of $75.96 and a 12 month high of $101.18. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 11.23. The business’s 50-day moving average price is $90.94 and its 200-day moving average price is $90.29. The company has a market cap of $79.19 billion, a P/E ratio of 39.07, a P/E/G ratio of 4.51 and a beta of 0.31.

Colgate-Palmolive (NYSE:CL – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Colgate-Palmolive had a return on equity of 607.88% and a net margin of 9.65%. The business had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.34 billion. During the same period last year, the company earned $0.91 EPS. Colgate-Palmolive’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, equities analysts expect that Colgate-Palmolive Company will post 3.92 EPS for the current year.

Colgate-Palmolive Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th were given a dividend of $0.53 per share. The ex-dividend date of this dividend was Tuesday, October 20th. This represents a $2.12 annualized dividend and a yield of 2.1%. Colgate-Palmolive’s dividend payout ratio is presently 83.14%.

Analyst Ratings Changes

Several research analysts have recently weighed in on CL shares. Deutsche Bank reaffirmed a “buy” rating and issued a $101.00 price target (up from $99.00) on shares of Colgate-Palmolive in a report on Monday, August 3rd. Piper Sandler dropped their price objective on Colgate-Palmolive from $98.00 to $95.00 and set an “overweight” rating for the company in a research note on Monday, September 21st. JPMorgan Chase & Co. reduced their target price on Colgate-Palmolive from $104.00 to $102.00 and set an “overweight” rating for the company in a research report on Monday, November 2nd. Royal Bank Of Canada lifted their price target on Colgate-Palmolive from $104.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday, November 2nd. Finally, Evercore raised their target price on shares of Colgate-Palmolive from $100.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $101.22.

Get Our Latest Analysis on CL

Colgate-Palmolive Profile

(Free Report)

Colgate-Palmolive is a global consumer products company whose business spans oral care, personal care, home care and pet nutrition. Its products include toothpaste, toothbrushes, mouthwashes, soaps, shampoos, cleaning products and pet food. The company’s best-known brands include Colgate, Palmolive, elmex, Softsoap, Ajax and Hill’s Pet Nutrition. It sells products through retail and other channels in markets around the world. Founded in 1806 by William Colgate as a soap and candle business in New York City, the company has grown into an international manufacturer of household and personal care products.

Read More

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL – Free Report).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.